432 related articles for article (PubMed ID: 27919103)
21. CE: Acute Pain Management for People with Opioid Use Disorder.
Broglio K; Matzo M
Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
[TBL] [Abstract][Full Text] [Related]
22. Medication-Assisted Treatment for Opioid-Use Disorder.
Oesterle TS; Thusius NJ; Rummans TA; Gold MS
Mayo Clin Proc; 2019 Oct; 94(10):2072-2086. PubMed ID: 31543255
[TBL] [Abstract][Full Text] [Related]
23. Primary care models for treating opioid use disorders: What actually works? A systematic review.
Lagisetty P; Klasa K; Bush C; Heisler M; Chopra V; Bohnert A
PLoS One; 2017; 12(10):e0186315. PubMed ID: 29040331
[TBL] [Abstract][Full Text] [Related]
24. Medication-Assisted Treatment of Adolescents With Opioid Use Disorders.
COMMITTEE ON SUBSTANCE USE AND PREVENTION
Pediatrics; 2016 Sep; 138(3):. PubMed ID: 27550978
[TBL] [Abstract][Full Text] [Related]
25. Use of Buprenorphine to Treat Opioid Use Disorder.
Bartholow LAM; Pope J
J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
[TBL] [Abstract][Full Text] [Related]
26. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
[TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapies for treating opioid use disorder.
Nguyen TA; Hahn JH; Strakowski SM
CNS Spectr; 2013 Dec; 18(6):289-95. PubMed ID: 23561653
[TBL] [Abstract][Full Text] [Related]
28. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.
Cheever LW; Kresina TF; Cajina A; Lubran R
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S3-6. PubMed ID: 21317591
[TBL] [Abstract][Full Text] [Related]
29. Models for integrating buprenorphine therapy into the primary HIV care setting.
Basu S; Smith-Rohrberg D; Bruce RD; Altice FL
Clin Infect Dis; 2006 Mar; 42(5):716-21. PubMed ID: 16447120
[TBL] [Abstract][Full Text] [Related]
30. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
Andraka-Christou B; Capone MJ
Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
[TBL] [Abstract][Full Text] [Related]
31. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.
Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP
J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023
[TBL] [Abstract][Full Text] [Related]
32. A mixed methods study of HIV-related services in buprenorphine treatment.
Knudsen HK; Cook J; Lofwall MR; Walsh SL; Studts JL; Havens JR
Subst Abuse Treat Prev Policy; 2017 Aug; 12(1):37. PubMed ID: 28814313
[TBL] [Abstract][Full Text] [Related]
33. Medication-assisted treatment for opioid use disorder.
Kaplan L
Nurse Pract; 2019 Mar; 44(3):10-12. PubMed ID: 30585906
[No Abstract] [Full Text] [Related]
34. The science and practice of medication-assisted treatments for opioid dependence.
Pecoraro A; Ma M; Woody GE
Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
[TBL] [Abstract][Full Text] [Related]
35. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
[TBL] [Abstract][Full Text] [Related]
36. Re-purposing anticoagulation clinics: expanding access to opioid agonist therapy in primary care settings.
Lagisetty P; Heisler M; Bohnert A
Addiction; 2017 Mar; 112(3):384-385. PubMed ID: 27550143
[No Abstract] [Full Text] [Related]
37. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.
Kampman K; Jarvis M
J Addict Med; 2015; 9(5):358-67. PubMed ID: 26406300
[TBL] [Abstract][Full Text] [Related]
38. Barriers and perceived usefulness of an ECHO intervention for office-based buprenorphine treatment for opioid use disorder in North Carolina: A qualitative study.
Shea CM; Gertner AK; Green SL
Subst Abus; 2021; 42(1):54-64. PubMed ID: 31809679
[TBL] [Abstract][Full Text] [Related]
39. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
[TBL] [Abstract][Full Text] [Related]
40. Overcoming Barriers to Initiating Medication-assisted Treatment for Heroin Use Disorder in a General Medical Hospital: A Case Report and Narrative Literature Review.
Hassamal S; Goldenberg M; Ishak W; Haglund M; Miotto K; Danovitch I
J Psychiatr Pract; 2017 May; 23(3):221-229. PubMed ID: 28492461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
